Portfolio News

Almaty, Kazakhstan, 13 July 2025 – MicroPort® CardioFlow has announced the first commercial implantations of its VitaFlow Liberty® Transcatheter Aortic Valve Implantation (TAVI) system in Kazakhstan. A total of four patients were treated at the JSC "Research Institute of Cardiology and Internal Diseases" in Almaty, one of the country’s leading centers for cardiovascular care.

The procedures were led by Dr. Alexey, a leading cardiologist in Kazakhstan, and jointly performed with Chinese specialists including Prof. Mao Chen and Prof. Yuan Feng from West China Hospital of Sichuan University. 

VitaFlow Liberty® builds upon the proven design of its predecessor, VitaFlow®, incorporating a hybrid-density self-expanding stent, bovine pericardial leaflets, and an advanced double-layer PET skirt. These features provide strong radial support, improved coaxial deployment, and reduced perivalvular leakage post-procedure. Furthermore, its next-generation delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.

Dr. Alexey noted, “The system offers greater control and flexibility during implantation, with excellent clinical precision. We look forward to continued collaboration to advance transcatheter techniques.”